Canadians face a longer-than-expected wait for cheaper versions of Novo Nordisk A/S’s diabetes drug Ozempic after two of the biggest generics makers were hit with additional requests from the health regulator.
Sandoz Group AG received a notice of deficiency from Health Canada — meaning a drug doesn’t yet meet regulatory requirements — for the Swiss drugmaker’s copycat version of semaglutide, Ozempic’s main ingredient, according to a person familiar with the matter who spoke on condition of anonymity.
Meanwhile Indian rival Dr. Reddy’s Laboratories Ltd. said in Octoberits own application doesn’t yet meet Health Canada’s standards, which Citigroup analyst ...
